COMMUNIQUÉS West-GlobeNewswire

Tetra Bio-Pharma Appoints Richard Giguère Chief Executive Officer of Tetra Natural Health
24/10/2018
ORLEANS, Ontario, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the appointment of Richard [...]
Natus Medical Announces Third Quarter Financial Results
24/10/2018
Reports record third quarter revenue of $130.6 million Reports third quarter GAAP loss per share of $0.17 and non-GAAP earnings per share of $0.40 Updates annual revenue and earnings guidance for 2018 PLEASANTON, Calif [...]
TRU NIAGEN® Daily Serving Strengthened Under FDA’s NDI Notification
24/10/2018
ChromaDex increases capsule serving to 150mg TRU NIAGEN ® (nicotinamide riboside), following successful New Dietary Ingredient (NDI) notification from FDA LOS ANGELES, Oct. 24, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. ( [...]
Emblem finalizes agreement to launch Emblem Germany in joint venture with Acnos Pharma
24/10/2018
Agreement will see Emblem export to one of the world’s largest legal medical cannabis markets TORONTO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX:EMMBF) ("Emblem" or the "Company"), today announced [...]
ViroGates releases third quarter 2018 results
24/10/2018
Company announcement no. 7-2018 Birkerød, 24 October 2018 ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems for emergency departments in hospitals, today reported financial results for [...]
Mesoblast Expands Partnership With JCR Pharmaceuticals for Treatment of Wound Healing in Epidermolysis Bullosa
24/10/2018
NEW YORK and MELBOURNE, Australia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced it has expanded its partnership with JCR Pharmaceuticals Co. Ltd. in Japan for wound healing [...]
Immunicum AB: Invitation to Investor Events in Gothenburg and Stockholm
24/10/2018
Press Release 24 October 2018 Immunicum AB: Invitation to Investor Events in Gothenburg and Stockholm Immunicum AB (publ; IMMU.ST) announced today that the Company will host two investor events in October. At both [...]
Orion and Amgen to collaborate on the commercialisation of AMGEVITA® (biosimilar adalimumab) in Finland
24/10/2018
Orion Corporation Press Release 24 October 2018 at 12.30 p.m. EEST Orion and Amgen to collaborate on the commercialisation of AMGEVITA ® (biosimilar adalimumab) in Finland Orion Corporation and Amgen have signed an [...]
Opthea To Present Update at the Ophthalmology Innovation Summit in Chicago
24/10/2018
MELBOURNE, Australia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, announced today that Dr [...]
Orion Group Interim Report January-September 2018
24/10/2018
ORION CORPORATION INTERIM REPORT JANUARY-SEPTEMBER 2018 24 OCTOBER 2018 at 12.00 EEST Orion Group Interim Report January-September 2018 Orion's net sales for continuing operations in January-September 2018 totalled EUR [...]
PCI Biotech: Capital increase registered and listing of new shares
24/10/2018
Oslo, Norway, 24 October 2018. Reference is made to the previous announcements by PCI Biotech Holding ASA ("PCI Biotech" or the "Company") in respect of the issuance of 170,000 new shares following exercise of employee [...]
EssilorLuxottica : Mise à disposition d'une note complémentaire au prospectus ayant reçu le visa n°18-460 de l'AMF le 28 septembre 2018
24/10/2018
Mise à disposition d'une note complémentaire au prospectus ayant reçu le visa n°18-460 de l'AMF le 28 septembre 2018 Version PDF du communiqué Charenton-le-Pont, France (24 octobre 2018 - 8h00) - EssilorLuxottica [...]
Rule 2.9 Announcement
24/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 24 October 2018 [...]
Interim report for the first nine months of 2018
24/10/2018
Read the full announcement in PDF Attachment 2018_60_Q32018_CompanyAnnouncement_EN_FINAL
Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met
24/10/2018
ORION CORPORATION STOCK EXCHANGE RELEASE 24 OCTOBER 2018 AT 8.30 a.m. EEST Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The [...]
Santhera Announces Start of Phase Ib/IIa Trial with POL6014 in Patients with Cystic Fibrosis
24/10/2018
Pratteln, Switzerland, October 24, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces the start of a Phase Ib/IIa multiple ascending dose (MAD) trial with POL6014 in patients with cystic fibrosis (CF). POL6014 is an [...]
ISS and Glass Lewis recommend ICC Shareholders vote FOR Arrangement with Aurora Cannabis
24/10/2018
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- ICC Labs Inc. (the Company or ICC ) (TSX-V: ICC) is pleased to announce that Institutional Shareholder Services Inc. ( ISS ) and Glass Lewis & Co. ( [...]
Lexington Provides Q3 Corporate Review
24/10/2018
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to review [...]
Psychemedics Announces Quarterly Results
23/10/2018
Declares 89 th Consecutive Quarterly Dividend ACTON, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2018 [...]

Pages